Home › Funds › United Super Pty Ltd in its capacity as Trustee for the Cons › GILD

United Super Pty Ltd in its capacity as Trustee for the Cons position in GILD

GILEAD SCIENCES INC · Health Care

United Super Pty Ltd in its capacity as Trustee for the Cons reported holding 304,796 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$45.4M, representing 0.60% of its reported portfolio and ranking #46 among its reported holdings. United Super Pty Ltd in its capacity as Trustee for the Cons has disclosed GILD holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)304.80K sh
Reported value held$45.43M
Portfolio Weight0.60%
First reportedQ4 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How United Super Pty Ltd in its capacity as Trustee for the Cons's GILD position evolved

United Super Pty Ltd in its capacity as Trustee for the Cons first disclosed a stake in GILD in Q4 2024 at 2,700 shares (US$249K). The position peaked in Q4 2025 at 450,096 shares, worth US$55.2M. Across 8 filings, United Super Pty Ltd in its capacity as Trustee for the Cons increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 304,796 shares valued at US$45.4M — a reduction of -53,600 shares quarter over quarter.. Notable position changes include a 263% increase in Q1 2025 (shares were roughly flat over the following quarter), a 132% increase in Q3 2025 (shares rose 10% over the following quarter), a 1679% increase in Q4 2025 (shares rose 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 2.70K $249.40K New
Q1 2025 9.80K $1.10M Add
Q2 2025 10.90K $1.21M Add
Q3 2025 25.30K $2.81M Add
Q4 2025 450.10K $55.24M Add
Q1 2026 365.40K $50.93M Reduce
Q2 2026 358.40K $45.28M Reduce
Q3 2026 304.80K $45.43M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 34 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has United Super Pty Ltd in its capacity as Trustee for the Cons held GILD?

United Super Pty Ltd in its capacity as Trustee for the Cons has disclosed GILD holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is United Super Pty Ltd in its capacity as Trustee for the Cons's current position in GILD?

As of Q3 2026, United Super Pty Ltd in its capacity as Trustee for the Cons holds 304.80K shares of GILD (GILEAD SCIENCES INC), valued at $45.43M, representing 0.60% of its reported portfolio and ranking #46.

Has United Super Pty Ltd in its capacity as Trustee for the Cons been buying or selling GILD?

In the latest 13F filing (Q3 2026), United Super Pty Ltd in its capacity as Trustee for the Cons reduced its position in GILD. The position peaked in Q4 2025 at 450.10K shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.